Theradaptive Receives US FDA Approval to Initiate P-III Trial of OsteoAdapt SP for Spinal Fusion Procedures

Why It Matters

The approval moves a potentially safer, more effective spinal fusion solution toward market, addressing a sizable unmet need for alternatives to autologous and allograft bone grafts.

Key Takeaways

• FDA greenlights OASIS Phase III trial for OsteoAdapt SP.
• OsteoAdapt SP leverages AMP2 rhBMP-2 for targeted bone growth.
• Trial covers TLIF, ALIF, and LLIF spinal fusion procedures.
• Prior data from ~100 patients supports safety and efficacy.
• Technology licensed from DHA’s Office of Medical Technology Transfer.

Pulse Analysis

Spinal fusion surgeries, driven by degenerative lumbar disease, rely heavily on bone grafts to achieve solid arthrodesis. Autologous grafts, while effective, pose donor‑site morbidity, and allografts carry infection and variability risks. The market has responded with synthetic and biologic substitutes, yet many lack consistent fusion rates. In this context, OsteoAdapt SP’s entry signals a shift toward engineered biologics that aim to combine efficacy with safety, potentially reshaping procurement strategies for hospitals and surgeons seeking reliable outcomes.

OsteoAdapt SP’s core is the AMP2 recombinant BMP‑2 (rhBMP‑2) variant, engineered for prolonged, localized release at the fusion site. By focusing growth factor activity, the device seeks to reduce ectopic bone formation—a known complication of earlier BMP products—while enhancing the speed and quality of new bone formation. Early-phase data from about 100 participants across the U.S., Australia, and Israel demonstrated comparable fusion rates to traditional grafts with a favorable adverse‑event profile, laying a data foundation that justified the FDA’s pivotal‑trial clearance.

The FDA’s endorsement of the OASIS Phase III study not only validates the pre‑clinical and early clinical work but also opens a pathway for broader commercial adoption if the trial meets its endpoints. The trial’s inclusion of TLIF, ALIF, and LLIF procedures covers the three most common lumbar fusion approaches, expanding the addressable market. Successful results could accelerate reimbursement negotiations, influence surgical guidelines, and intensify competition among spine‑technology firms, ultimately driving innovation and potentially lowering costs for a procedure that accounts for billions of dollars in annual U.S. healthcare spending.